Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

被引：0
|
作者：
Sizheng Zhao
Laura Chadwick
Eduardo Mysler
Robert J. Moots
机构：
[1] University of Liverpool,Department of Musculoskeletal Biology I, Clinical Sciences Centre, Institute of Ageing and Chronic Disease
[2] Aintree University Hospital,undefined
[3] Organización Medica de Investigación,undefined
来源：
Current Rheumatology Reports | 2018年 / 20卷
关键词：
Adalimumab; Biosimilar; Rheumatoid arthritis; Amgevita; Cyltezo; Imraldi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
    Tom W. J. Huizinga
    Yoshifumi Torii
    Rafael Muniz
    Rheumatology and Therapy, 2021, 8 : 41 - 61
  • [32] A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis
    Bellinvia, Salvatore
    Ashraf, Madiha
    Polosa, Riccardo
    Edwards, Christopher
    IMMUNOTHERAPY, 2017, 9 (14) : 1133 - 1142
  • [33] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
    Roy M. Fleischmann
    Daniel F. Alvarez
    Amy E. Bock
    Carol Cronenberger
    Ivana Vranic
    Wuyan Zhang
    Rieke Alten
    Arthritis Research & Therapy, 23
  • [34] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial
    Fleischmann, Roy M.
    Alvarez, Daniel F.
    Bock, Amy E.
    Cronenberger, Carol
    Vranic, Ivana
    Zhang, Wuyan
    Alten, Rieke
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [35] Pneumocystosis in a patient with rheumatoid arthritis on adalimumab therapy: a case-based review
    Dimitris C. Kounatidis
    Vasileios Papadimitropoulos
    Konstantinos Avramidis
    Evgenia Plenga
    Ioanna Tsiara
    Elena Avgoustou
    Natalia Vallianou
    Dimitrios Vassilopoulos
    Rheumatology International, 2024, 44 : 363 - 367
  • [36] Pneumocystosis in a patient with rheumatoid arthritis on adalimumab therapy: a case-based review
    Kounatidis, Dimitris C.
    Papadimitropoulos, Vasileios
    Avramidis, Konstantinos
    Plenga, Evgenia
    Tsiara, Ioanna
    Avgoustou, Elena
    Vallianou, Natalia
    Vassilopoulos, Dimitrios
    RHEUMATOLOGY INTERNATIONAL, 2024, 44 (02) : 363 - 367
  • [37] Role of adalimumab in the treatment of early rheumatoid arthritis
    Keystone, EC
    Haraoui, B
    Bykerk, VP
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2003, 21 (05) : S198 - S199
  • [38] Adalimumab for early rheumatoid arthritis
    Bykerk, Vivian Patricia
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2008, 4 (02) : 157 - 163
  • [39] Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
    Jin, Ran
    Haughton, James M.
    Goddard, Emily J.
    Courmier, Delphine
    Radziszewski, Waldemar
    Meadows, Rachael H.
    Piercy, James
    Cohen, Stanley
    RHEUMATOLOGY AND THERAPY, 2025, : 469 - 492
  • [40] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Markus, Richard
    McBride, Helen J.
    Ramchandani, Monica
    Chow, Vincent
    Liu, Jennifer
    Mytych, Dan
    Fanjiang, Gary
    ADVANCES IN THERAPY, 2019, 36 (08) : 1833 - 1850
12345